Flora Y Kim, NP
Nurse Practitioner · New York
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 11 years
- Graduated 2015
Offices
2 locations · Trustees of Columbia University in the City of New York · Columbia Doctors of New Jersey P C
Hospitals listed: New York-Presbyterian Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Flora Y Kim’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- New York-Presbyterian HospitalNew York, NYAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of New York Presbyterian Healthcare System, which runs 8 hospitalsHome of Herbert Irving Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 15.2 (13.8 to 16.7) · 1,897 cases, Jan 2024 – Dec 2024Better than the national rate — Abdominopelvic accidental puncture or laceration rate: 0.35 (0 to 0.86) · 10,364 cases, Jul 2022 – Jun 2024Better than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.4 (0.3 to 0.51), Jul 2022 – Jun 2024Better than the national rate — In-hospital fall-associated fracture rate: 0.14 (0.03 to 0.25) · 52,654 cases, Jul 2022 – Jun 2024Better than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 1.48 (0.6 to 2.36) · 14,926 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative acute kidney injury requiring dialysis rate: 0.48 (0 to 1.06) · 8,078 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative hemorrhage or hematoma rate: 0.94 (0.21 to 1.66) · 12,529 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative respiratory failure rate: 6.15 (4.51 to 7.79) · 8,277 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative sepsis rate: 1.66 (0.42 to 2.91) · 8,436 cases, Jul 2022 – Jun 2024Better than the national rate — Pressure ulcer rate: 0.09 (0 to 0.3) · 44,511 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.575, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.632, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.22, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.743, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 3.6 (2.9 to 4.4) · 1,897 cases, Jan 2024 – Dec 2024Better than the national rate — Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies): 10.6 (8.9 to 12.6) · 7,950 cases, Jan 2022 – Dec 2024Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.6 (0.6 to 0.7) · 4,225 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for New York-Presbyterian Hospital
Behind the star rating — Deaths: 6 better, 2 the same, 0 worse of 8 measures. Safety: 4 better, 4 the same, 0 worse of 8 measures. Readmissions: 3 better, 6 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 15.2 (13.8 to 16.7) · 1,897 cases | Worse | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.35 (0 to 0.86) · 10,364 cases | Better | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.4 (0.3 to 0.51) | Better | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.14 (0.03 to 0.25) · 52,654 cases | Better | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 1.48 (0.6 to 2.36) · 14,926 cases | Better | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.48 (0 to 1.06) · 8,078 cases | Better | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 0.94 (0.21 to 1.66) · 12,529 cases | Better | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.15 (4.51 to 7.79) · 8,277 cases | Better | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 1.66 (0.42 to 2.91) · 8,436 cases | Better | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.09 (0 to 0.3) · 44,511 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.575 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.632 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.22 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.743 | Better | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 3.6 (2.9 to 4.4) · 1,897 cases | Better | Jan 2024 – Dec 2024 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 10.6 (8.9 to 12.6) · 7,950 cases | Better | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.6 (0.6 to 0.7) · 4,225 cases | Better | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 156.83 (135.92 to 177.74) · 798 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 382 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 5.7 · 574 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.6 · 616 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.9 · 2,532 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.9 · 3,140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 7.7 · 1,821 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 1.8 · 24,470 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.11 (0 to 0.22) · 48,588 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 0.84 (0 to 1.9) · 3,187 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 1,240 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0.314 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.6 · 1,045 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.4 · 5,234 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 11 · 686 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 3 · 2,938 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 13.4 · 3,258 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 5,005 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 1,230 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 411 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 1,226 cases | None | Jul 2023 – Jun 2025 |
What patients said (2,640 patients answered, 20% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$6,554
Medicare paid this office $6,554 for 35 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 34 | $6,390 | $133 |
Who their Medicare patients are
35 Original Medicare patients in 2024. Average age 66 · 85 and older 0% · Women 57% · Health risk score 3.96. Sicker patients than 9 in 10 peers; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 75% · Chronic kidney disease 74% · Diabetes 60% · COPD 51% · Coronary heart disease 43% · Atrial fibrillation 40% · Depression 31%.
The office billed $36,400, Medicare allowed $8,259 and paid $6,554; for 49 services of 2 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 35 | 49 | 66 | 3.96 | $36,400 | $6,554 |
| 2023 | 40 | 45 | 71 | 5.77 | $14,256 | $4,255 |
| 2022 | 30 | 32 | 66 | 3.93 | $9,499 | $2,926 |
| 2018 | 31 | 31 | 71 | 2.10 | $4,163 | $2,621 |
| 2017 | 24 | 24 | 70 | 3.28 | $6,839 | $2,290 |
| 2016 | 15 | 23 | 63 | 3.29 | $8,985 | $2,441 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Long return visit (40+ min) | 38 | $4,121 | $98 |
2022: 1 service
| Long return visit (40+ min) | 22 | $2,313 | $101 |
2018: 1 service
| New patient visit (45+ min) | 17 | $1,666 | $98 |
2017: 1 service
| Long return visit (40+ min) | 11 | $1,127 | $102 |
2016: 1 service
| Long return visit (40+ min) | 15 | $2,360 | $107 |
Drugs they prescribed that Part D paid
$735,920
Pharmacies billed $735,920 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (23 of 1,866) in 2024. Above the middle of the specialty; the typical nurse practitioner clinician is at 0%.
1,528 generic and 231 brand-name prescriptions · $735,920 in drug cost · 271 antibiotic prescriptions to 74 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prevymis | None | 23 | $166,015 | $7,218 |
| Gammaked | Immune globulin | 13 | $152,696 | $11,746 |
| Privigen | Immune globulin | 12 | $57,126 | $4,760 |
| Posaconazole | None | 39 | $45,584 | $1,169 |
| Eliquis | None | 49 | $32,078 | $655 |
See all 41 drugs
| Prevymis | None | 23 | $166,015 | $7,218 |
| Gammaked | Immune globulin | 13 | $152,696 | $11,746 |
| Privigen | Immune globulin | 12 | $57,126 | $4,760 |
| Posaconazole | None | 39 | $45,584 | $1,169 |
| Eliquis | None | 49 | $32,078 | $655 |
| Tacrolimus | None | 125 | $12,410 | $99 |
| Valganciclovir | None | 44 | $11,497 | $261 |
| Ozempic | None | 11 | $10,215 | $929 |
| Aranesp | None | 11 | $9,064 | $824 |
| Atovaquone | None | 18 | $6,203 | $345 |
| Mycophenolic Acid | None | 13 | $4,251 | $327 |
| Mycophenolate Mofetil | None | 20 | $2,315 | $116 |
| Valacyclovir | None | 29 | $1,527 | $53 |
| Azithromycin | None | 81 | $1,157 | $14 |
| Prednisone | None | 98 | $944 | $10 |
| Metoprolol | None | 37 | $754 | $20 |
| Sulfamethoxazole-Trimethoprim | None | 121 | $700 | $6 |
| Famotidine | None | 63 | $639 | $10 |
| Prenatal Vitamin Plus Low Iron | None | 71 | $592 | $8 |
| Ultra-Fine Short Pen Needle | None | 11 | $578 | $53 |
| Omeprazole | None | 40 | $554 | $14 |
| Gabapentin | None | 57 | $551 | $10 |
| Azathioprine | None | 23 | $547 | $24 |
| Labetalol | None | 15 | $434 | $29 |
| Clotrimazole | None | 13 | $389 | $30 |
| Pantoprazole | None | 22 | $380 | $17 |
| Amlodipine Besylate | None | 40 | $254 | $6 |
| Alendronate | None | 41 | $232 | $6 |
| Rosuvastatin | None | 24 | $222 | $9 |
| Atorvastatin | None | 31 | $208 | $7 |
| Levofloxacin | None | 25 | $153 | $6 |
| Sertraline | None | 18 | $146 | $8 |
| Fludrocortisone Acetate | None | 12 | $142 | $12 |
| Zolpidem | None | 18 | $126 | $7 |
| Ondansetron | None | 12 | $117 | $10 |
| Losartan | None | 14 | $94 | $7 |
| Hydralazine | None | 12 | $86 | $7 |
| Vitamin D2 | None | 14 | $50 | $4 |
| Amoxicillin | None | 19 | $41 | $2 |
| Furosemide | None | 14 | $38 | $3 |
| Metoprolol | None | 13 | $30 | $2 |
Year by year
| 2024 | 1,866 | 138 | 1% (23) | 12% | $735,920 |
| 2023 | 308 | 102 | None | None | $239,761 |
| 2022 | 215 | 78 | None | 14% | $169,156 |
| 2021 | 126 | 46 | None | 10% | $23,726 |
| 2020 | 691 | 45 | 2% (11) | None | $82,517 |
| 2019 | 326 | 14 | 0% (0) | None | $120,661 |
| 2018 | 294 | 59 | None | None | $102,409 |
| 2017 | 2,743 | 177 | 1% (14) | 14% | $750,279 |
| 2016 | 2,976 | 182 | 2% (45) | 19% | $960,168 |
| 2015 | 120 | 40 | None | None | $59,125 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Eliquis | 16 | $15,380 | $961 |
| Valganciclovir | 14 | $4,490 | $321 |
| Tacrolimus | 19 | $2,644 | $139 |
| Prednisone | 25 | $132 | $5 |
2022: 3 drugs
| Gabapentin | 14 | $633 | $45 |
| Azithromycin | 11 | $171 | $16 |
| Prednisone | 11 | $67 | $6 |
2021: 2 drugs
| Pantoprazole | 19 | $189 | $10 |
| Sulfamethoxazole-Trimethoprim | 12 | $40 | $3 |
2020: 14 drugs
| Valganciclovir | 51 | $30,246 | $593 |
| Voriconazole | 25 | $12,869 | $515 |
| Tacrolimus | 28 | $8,382 | $299 |
| Itraconazole | 20 | $5,015 | $251 |
| Enoxaparin | 12 | $3,319 | $277 |
| Mycophenolate Mofetil | 13 | $1,572 | $121 |
| Pantoprazole | 57 | $702 | $12 |
| Nystatin | 22 | $628 | $29 |
| Prednisone | 67 | $403 | $6 |
| Sulfamethoxazole-Trimethoprim | 72 | $330 | $5 |
| Gabapentin | 31 | $291 | $9 |
| Metoprolol | 39 | $275 | $7 |
| Furosemide | 25 | $108 | $4 |
| Amlodipine Besylate | 17 | $47 | $3 |
2019: 9 drugs
| Valganciclovir | 42 | $39,279 | $935 |
| Itraconazole | 28 | $25,117 | $897 |
| Clotrimazole | 27 | $2,724 | $101 |
| Tacrolimus | 16 | $696 | $44 |
| Prednisone | 22 | $238 | $11 |
| Pantoprazole | 44 | $195 | $4 |
| Pravastatin | 11 | $161 | $15 |
| Sulfamethoxazole-Trimethoprim | 34 | $88 | $3 |
| Metoprolol | 13 | $45 | $3 |
2018: 7 drugs
| Valganciclovir | 25 | $27,549 | $1,102 |
| Itraconazole | 11 | $11,750 | $1,068 |
| Clotrimazole | 17 | $947 | $56 |
| Pantoprazole | 21 | $249 | $12 |
| Prednisone | 23 | $193 | $8 |
| Sulfamethoxazole-Trimethoprim | 24 | $123 | $5 |
| Metoprolol | 12 | $32 | $3 |
2017: 56 drugs
| Valganciclovir | None | 105 | $185,924 | $1,771 |
| Noxafil | None | 21 | $117,615 | $5,601 |
| Creon | None | 25 | $104,207 | $4,168 |
| Atovaquone | None | 31 | $49,527 | $1,598 |
| Privigen | Immune globulin | 11 | $40,189 | $3,654 |
| Tacrolimus | None | 80 | $11,678 | $146 |
| Prograf | None | 12 | $10,098 | $841 |
| Ursodiol | None | 27 | $8,796 | $326 |
| Novolog | None | 13 | $7,352 | $566 |
| Lyrica | None | 16 | $6,857 | $429 |
| Mycophenolate Mofetil | None | 53 | $5,936 | $112 |
| Enoxaparin | None | 18 | $5,418 | $301 |
| Esomeprazole Magnesium | None | 33 | $4,751 | $144 |
| Advair Diskus | None | 12 | $3,640 | $303 |
| Nexium | None | 12 | $3,074 | $256 |
| Azithromycin | None | 161 | $2,941 | $18 |
| Nystatin | None | 58 | $2,453 | $42 |
| Cyclosporine Modified | None | 15 | $2,374 | $158 |
| Omega-3 Acid Ethyl Esters | None | 19 | $2,159 | $114 |
| Metoprolol | None | 58 | $2,099 | $36 |
| Potassium Citrate Er | None | 12 | $1,962 | $164 |
| Azathioprine | None | 27 | $1,941 | $72 |
| Clotrimazole | None | 25 | $1,907 | $76 |
| Prednisone | None | 189 | $1,638 | $9 |
| Sulfamethoxazole-Trimethoprim | None | 234 | $1,582 | $7 |
| Humalog Kwikpen U-100 | None | 11 | $1,544 | $140 |
| Acyclovir | None | 16 | $1,418 | $89 |
| Pravastatin | None | 70 | $1,405 | $20 |
| Gabapentin | None | 72 | $1,117 | $16 |
| Rosuvastatin | None | 15 | $1,112 | $74 |
| Propranolol | None | 43 | $969 | $23 |
| Omeprazole | None | 90 | $940 | $10 |
| Levothyroxine | None | 53 | $919 | $17 |
| Duloxetine | None | 22 | $894 | $41 |
| Alendronate | None | 117 | $811 | $7 |
| Metoprolol | None | 87 | $699 | $8 |
| Atorvastatin | None | 28 | $604 | $22 |
| Pantoprazole | None | 27 | $465 | $17 |
| Amlodipine Besylate | None | 42 | $464 | $11 |
| Fluticasone Propionate | None | 24 | $461 | $19 |
| Prenatal Plus | None | 17 | $441 | $26 |
| Tamsulosin | None | 20 | $347 | $17 |
| Hydralazine | None | 14 | $285 | $20 |
| Prenatal Vitamin Plus Low Iron | None | 45 | $283 | $6 |
| Alcohol Prep Pads | None | 17 | $262 | $15 |
| Warfarin | None | 14 | $256 | $18 |
| Levofloxacin | None | 22 | $253 | $11 |
| Famotidine | None | 35 | $229 | $7 |
| Valacyclovir | None | 11 | $217 | $20 |
| Sodium Chloride | None | 19 | $211 | $11 |
| Megestrol Acetate | None | 11 | $209 | $19 |
| Losartan | None | 18 | $208 | $12 |
| Mirtazapine | None | 16 | $107 | $7 |
| Sertraline | None | 12 | $104 | $9 |
| Diphenhydramine | None | 14 | $58 | $4 |
| Amoxicillin | None | 15 | $28 | $2 |
2016: 66 drugs
| Noxafil | 31 | $174,662 | $5,634 |
| Creon | 39 | $164,053 | $4,206 |
| Valganciclovir | 68 | $124,892 | $1,837 |
| Valcyte | 23 | $64,742 | $2,815 |
| Atovaquone | 56 | $63,921 | $1,141 |
| Tacrolimus | 92 | $12,866 | $140 |
| Spiriva | 24 | $11,973 | $499 |
| Advair Diskus | 38 | $11,195 | $295 |
| Ursodiol | 42 | $10,553 | $251 |
| Vancomycin | 12 | $8,724 | $727 |
| Lyrica | 23 | $7,920 | $344 |
| Enoxaparin | 14 | $7,580 | $541 |
| Esomeprazole Magnesium | 27 | $5,645 | $209 |
| Nexium | 16 | $5,371 | $336 |
| Neoral | 12 | $5,108 | $426 |
| Crestor | 20 | $5,026 | $251 |
| Mycophenolate Mofetil | 60 | $4,926 | $82 |
| Nystatin | 64 | $3,126 | $49 |
| Clotrimazole | 26 | $2,606 | $100 |
| Azithromycin | 115 | $2,407 | $21 |
| Fluconazole | 17 | $2,068 | $122 |
| Azathioprine | 21 | $1,825 | $87 |
| Metoprolol | 44 | $1,519 | $35 |
| Omeprazole | 137 | $1,334 | $10 |
| Prednisone | 190 | $1,316 | $7 |
| Warfarin | 44 | $1,291 | $29 |
| Gabapentin | 101 | $1,160 | $11 |
| Rosuvastatin | 13 | $1,123 | $86 |
| Levothyroxine | 59 | $1,099 | $19 |
| Propranolol | 41 | $1,092 | $27 |
| Polyethylene Glycol 3350 | 12 | $1,092 | $91 |
| Sulfamethoxazole-Trimethoprim | 168 | $1,049 | $6 |
| Pravastatin | 51 | $1,026 | $20 |
| Duloxetine | 18 | $934 | $52 |
| Labetalol | 14 | $851 | $61 |
| Levofloxacin | 43 | $845 | $20 |
| Bd Ultra-Fine Pen Needle | 16 | $803 | $50 |
| Alendronate | 119 | $740 | $6 |
| Atorvastatin | 48 | $634 | $13 |
| Valacyclovir | 18 | $573 | $32 |
| Metoprolol | 73 | $537 | $7 |
| Pantoprazole | 25 | $375 | $15 |
| Tamsulosin | 21 | $369 | $18 |
| Amlodipine Besylate | 48 | $339 | $7 |
| Prenatal Plus | 13 | $332 | $26 |
| Zolpidem | 14 | $270 | $19 |
| Fluticasone Propionate | 17 | $221 | $13 |
| Ondansetron | 24 | $221 | $9 |
| Oxycodone | 12 | $216 | $18 |
| Losartan | 24 | $206 | $9 |
| Alcohol Prep Pads | 11 | $201 | $18 |
| Fluoxetine | 23 | $200 | $9 |
| Megestrol Acetate | 15 | $171 | $11 |
| Escitalopram | 15 | $164 | $11 |
| Sertraline | 15 | $157 | $10 |
| Famotidine | 32 | $151 | $5 |
| Prenatal Vitamin Plus Low Iron | 15 | $146 | $10 |
| Klor-Con M20 | 11 | $124 | $11 |
| Amoxicillin-Clavulanate Potass | 11 | $124 | $11 |
| Tramadol | 16 | $117 | $7 |
| Simvastatin | 14 | $113 | $8 |
| Mirtazapine | 25 | $112 | $4 |
| Nizatidine | 11 | $112 | $10 |
| Metoclopramide | 15 | $111 | $7 |
| Furosemide | 17 | $76 | $4 |
| Amoxicillin | 22 | $53 | $2 |
Money from drug and device companies
$65 in 2025
| 2025 | 2 | 2 | None | $65 |
| 2024 | 2 | 5 | None | $132 |
| 2023 | 6 | 16 | None | $482 |
| 2022 | 2 | 6 | None | $131 |
| 2021 | 1 | 2 | None | $248 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Creon | $35 | 1 payment
|
| Astellas Pharma US | Cresemba | $30 | 1 payment
|
See all 2 published payments
| Astellas Pharma US | Meals · 2025-10-09 | Cresemba | $30 |
| Abbvie | Meals · 2025-06-26 | Creon | $35 |
See earlier years (2024, 2023, 2022, 2021)
2024: $132
| Insmed | Arikayce | $104 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $28 | 1 payment
|
2023: $482
| Boehringer Ingelheim Pharmaceuticals | Ofev | $111 | 5 payments
|
| Astellas Pharma US | Cresemba | $105 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $94 | 1 payment
|
| Insmed | Arikayce | $86 | 3 payments
|
| Grifols USA | Prolastin-C Liquid | $60 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Livtencity | $25 | 1 payment
|
2022: $131
| Astellas Pharma US | Cresemba | $86 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $45 | 2 payments
|
2021: $248
| AstraZeneca Pharmaceuticals LP | Breztri | $248 | 2 payments
|
Professional record
- NPI
- 1578930152
- Licence
- CA 95006254, NY 430930
- Group
- Trustees of Columbia University in the City of New York · Columbia Doctors of New Jersey P C
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 363LA2100X (363LA2100X); Nurse practitioner (363L00000X)
- Mailing address
- 630 W 168th St # 4, New York, NY, 10032
- NPI first listed
- 2015-08-30
- NPI last updated
- 2023-07-12
- NPI record certified
- 2023-07-12
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305